NYSE:MDT - Medtronic Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$93.72 -1.78 (-1.86 %)
(As of 12/16/2018 03:52 PM ET)
Previous Close$93.72
Today's Range$93.1150 - $94.76
52-Week Range$76.41 - $100.15
Volume6.33 million shs
Average Volume5.55 million shs
Market Capitalization$125.87 billion
P/E Ratio18.82
Dividend Yield2.13%
Beta0.96
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:MDT
Previous Symbol
CUSIP58505510
Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.48
Current Ratio2.56
Quick Ratio2.11

Price-To-Earnings

Trailing P/E Ratio18.82
Forward P/E Ratio18.27
P/E Growth2.44

Sales & Book Value

Annual Sales$29.95 billion
Price / Sales4.20
Cash Flow$6.7570 per share
Price / Cash Flow13.87
Book Value$37.02 per share
Price / Book2.53

Profitability

EPS (Most Recent Fiscal Year)$4.77
Net Income$3.10 billion
Net Margins7.44%
Return on Equity13.51%
Return on Assets7.45%

Miscellaneous

Employees86,000
Outstanding Shares1,343,050,000
Market Cap$125.87 billion
OptionableOptionable

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Friday, December 7th. Shareholders of record on Friday, December 28th will be given a dividend of $0.50 per share on Friday, January 18th. This represents a $2.00 annualized dividend and a yield of 2.13%. The ex-dividend date of this dividend is Thursday, December 27th. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic announced that its Board of Directors has initiated a stock repurchase plan on Thursday, October 5th 2017, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 49% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) released its quarterly earnings results on Tuesday, November, 20th. The medical technology company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.15 by $0.07. The medical technology company earned $7.48 billion during the quarter, compared to analyst estimates of $7.35 billion. Medtronic had a return on equity of 13.51% and a net margin of 7.44%. The company's quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Medtronic.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic issued an update on its third quarter earnings guidance on Tuesday, November, 20th. The company provided earnings per share guidance of $1.23-1.25 for the period. Medtronic also updated its FY 2019 guidance to $5.10-5.15 EPS.

What price target have analysts set for MDT?

19 Wall Street analysts have issued 1 year price objectives for Medtronic's shares. Their predictions range from $88.00 to $120.00. On average, they expect Medtronic's stock price to reach $104.8611 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View Analyst Price Targets for Medtronic.

What is the consensus analysts' recommendation for Medtronic?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 6 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.

Has Medtronic been receiving favorable news coverage?

News stories about MDT stock have trended positive on Sunday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medtronic earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the next several days.

Who are some of Medtronic's key competitors?

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 62)
  • Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
  • Mr. Mark Ploof, Sr. VP of Global Operations and Bus. Services

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.10%), Vanguard Group Inc (8.15%), BlackRock Inc. (7.21%), Massachusetts Financial Services Co. MA (4.25%), Franklin Resources Inc. (2.08%) and Dodge & Cox (1.31%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Michael J Coyle, Omar Ishrak, Richard H Anderson and Richard Kuntz. View Institutional Ownership Trends for Medtronic.

Which institutional investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, The Manufacturers Life Insurance Company, Sanders Capital LLC, Dodge & Cox, Massachusetts Financial Services Co. MA and Wells Fargo & Company MN. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hooman Hakami, James T Lenehan, Michael J Coyle and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which institutional investors are buying Medtronic stock?

MDT stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Nordea Investment Management AB, Pendal Group Ltd, Renaissance Technologies LLC, Man Group plc, American Century Companies Inc., FMR LLC and Marshall Wace North America L.P.. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $93.72.

How big of a company is Medtronic?

Medtronic has a market capitalization of $125.87 billion and generates $29.95 billion in revenue each year. The medical technology company earns $3.10 billion in net income (profit) each year or $4.77 on an earnings per share basis. Medtronic employs 86,000 workers across the globe.

What is Medtronic's official website?

The official website for Medtronic is http://www.medtronic.com.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (NYSE MDT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,116 (Vote Outperform)
Underperform Votes:  683 (Vote Underperform)
Total Votes:  1,799
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel